Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Mylan Seeks To Overturn FDA's Provigil Decision

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/05/2012 | 07:10pm CET

Mylan Inc. (>> Mylan Inc.) said it is seeking to overturn a decision by the U.S. Food and Drug Administration that awarded Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) exclusivity for its generic version of Cephalon Inc.'s wakefulness drug Provigil.

The generic drug maker said Thursday it has filed a lawsuit against the FDA in the U.S. district court for the District of Columbia. Mylan is seeking an immediate court order entitling it to exclusivity as well as immediate approval for its abbreviated new drug application.

Mylan alleges Teva did not maintain valid certifications as a result of its acquisition last year of Cephalon and thus is not entitled to exclusivity based on patent certifications. Mylan also alleges that the FDA should have found Mylan as the sole first filer on one of the patents for Provigil.

Earlier Thursday, Teva said the FDA has decided that Teva is the sole first-to-file for both of Provigil's patents, which entitled the company to 180-day exclusivity. The FDA decided that Cephalon's launch of generic Provigil on March 29 triggered the exclusivity.

In October, the Federal Trade Commission required Teva to sell the rights and assets related to a generic cancer pain drug and a generic muscle relaxant in connection with Teva's acquisition of Cephalon. The FTC agreement also required Teva to enter a supply agreement that allows a competing firm, Par Pharmaceuticals Inc. (PRX), to sell a generic version of Provigil in 2012.

Teva expects Par Pharmaceuticals to launch a second generic product on April 6.

Mylan shares slipped 1.8% to $22.74 in recent trading. The stock is up 5.9% so far this year.

 
   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com 

Stocks mentioned in the article : Mylan Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MYLAN INC
02/24MYLAN NV : annual earnings release
02/17 MYLAN NV : Blog Coverage The Biologics License Application for Mylan-Biocon's Pr..
02/16 MYLAN : U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Bioco..
02/14 MYLAN : Applauds the Generic Pharmaceutical Association's Rebrand to the Associa..
02/08 Weak pound buoys GSK but drugmaker warns on 2017 generic threat
02/06 MYLAN : agreed to pay $96.5 million in Provigil antitrust class action
02/03 MYLAN : to Host Investor Day on March 1, 2017 in New York City
02/01DJMore Headaches for Drugmakers -- WSJ
01/31 MYLAN : Wins U.S. District Court Ruling Related to Copaxone® 40 mg/mL Patents
01/30 As Teva wins U.S. approval for GSK Advair copy, main fight yet to come
More news
Sector news : Pharmaceuticals - NEC
09:38pDJJOHNSON & JOHNSON : Prescription Unit List Prices Rose 8.5% Last Year
06:13p FTSE ends higher on some positive earnings, insurers slip
08:06aDJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Advertisement
Financials ($)
Sales 2016 11 009 M
EBIT 2016 3 190 M
Net income 2016 1 054 M
Debt 2016 11 910 M
Yield 2016 -
P/E ratio 2016 30,85
P/E ratio 2017 15,18
EV / Sales 2016 3,13x
EV / Sales 2017 2,67x
Capitalization 22 560 M
More Financials
Chart MYLAN INC
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 49,6 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC-1.66%22 560
JOHNSON & JOHNSON6.53%333 891
ROCHE HOLDING LTD.5.42%210 192
PFIZER INC.5.48%207 902
NOVARTIS AG4.72%202 648
MERCK & CO., INC.12.38%182 412
More Results